Repurposing raltegravir for reducing inflammation and treating cancer: a bioinformatics analysis
Zahra Nikfarjam, Reza Rakhshi, Farshid Zargari, Mahdi Aalikhani, Amin Moradi Hasan-Abad, Zahra Bazi · 2024
Read Repurposing raltegravir for reducing inflammation and treating cancer: a bioinformatics analysis by Zahra Nikfarjam, Reza Rakhshi, Farshid Zargari, Mahdi Aalikhani, Amin Moradi Hasan-Abad, Zahra Bazi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11621354.txt.
Description
Zahra Nikfarjam and co-authors explored a second career for an HIV drug using computer analysis in a 2024 paper. The drug, raltegravir, blocks a viral enzyme. Inflammation drives many diseases, and one enzyme, ADAM17, switches on a host of inflammatory and growth factors. When it misfires, growth and inflammation both accelerate.
Their bioinformatics study mapped how raltegravir might interact with inflammation and cancer pathways beyond its viral target. Network analysis can surface such repurposing leads cheaply, before any lab work. Candidates that survive screening earn cell and animal tests. The paper adds a worked example of drug repurposing, a strategy prized when new drug development is slow and costly.
Catalog record
| CREATOR | Zahra Nikfarjam, Reza Rakhshi, Farshid Zargari, Mahdi Aalikhani, Amin Moradi Hasan-Abad, Zahra Bazi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |